President Trump announced Regeneron's agreement to reduce drug prices for Medicaid and offer cholesterol medicine Praluent at $225, marking the completion of 17 drug pricing deals. This development signals a significant shift in pharmaceutical pricing strategies that could influence how tech professionals approach healthtech solutions and collaborations with pharma companies. Additionally, Regeneron received FDA approval for Otarmeni, the first gene therapy under the National Priority Voucher program, which may set a precedent for future gene therapies.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



